메뉴 건너뛰기




Volumn 8, Issue 3, 2013, Pages

A Randomized Controlled Trial of the Efficacy and Safety of CCX282-B, an Orally-Administered Blocker of Chemokine Receptor CCR9, for Patients with Crohn's Disease

(15)  Keshav, Satish a   Vaňásek, Tomáš b   Niv, Yaron c   Petryka, Robert d   Howaldt, Stephanie e   Bafutto, Mauro f   Rácz, István g   Hetzel, David h   Nielsen, Ole Haagen i   Vermeire, Séverine j   Reinisch, Walter k   Karlén, Per l   Schreiber, Stefan m   Schall, Thomas J n   Bekker, Pirow n  


Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CCX 282B; CORTICOSTEROID; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PLACEBO; UNCLASSIFIED DRUG; VERCIRNON;

EID: 84875195096     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060094     Document Type: Article
Times cited : (128)

References (20)
  • 1
    • 0016799492 scopus 로고
    • Clinical patterns in Crohn's disease: a statistical study of 615 cases
    • Farmer RG, Hawk WA, Turnbull RB Jr, (1975) Clinical patterns in Crohn's disease: a statistical study of 615 cases. Gastroenterology 68: 627-635.
    • (1975) Gastroenterology , vol.68 , pp. 627-635
    • Farmer, R.G.1    Hawk, W.A.2    Turnbull Jr., R.B.3
  • 2
    • 32144454172 scopus 로고    scopus 로고
    • The many roles of chemokines and chemokine receptors in inflammation
    • Charo IF, Ransohoff RM, (2006) The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 354: 610-21.
    • (2006) N Engl J Med , vol.354 , pp. 610-621
    • Charo, I.F.1    Ransohoff, R.M.2
  • 3
    • 0033231492 scopus 로고    scopus 로고
    • Human G protein-coupled receptor GPR-9-6/CC chemokine receptor 9 is selectively expressed on intestinal homing T lymphocytes, mucosal lymphocytes, and thymocytes and is required for thymus-expressed chemokine-mediated chemotaxis
    • Zabel BA, Agace WW, Campbell JJ, Heath HM, Parent D, et al. (1999) Human G protein-coupled receptor GPR-9-6/CC chemokine receptor 9 is selectively expressed on intestinal homing T lymphocytes, mucosal lymphocytes, and thymocytes and is required for thymus-expressed chemokine-mediated chemotaxis. J Exp Med 190: 1241-1256.
    • (1999) J Exp Med , vol.190 , pp. 1241-1256
    • Zabel, B.A.1    Agace, W.W.2    Campbell, J.J.3    Heath, H.M.4    Parent, D.5
  • 4
    • 0344483879 scopus 로고    scopus 로고
    • Cutting edge: identification of the orphan chemokine receptor GPR-9-6 as CCR9, the receptor for the chemokine TECK
    • Zaballos A, Gutierrez J, Varona R, Ardavin C, Márquez G, (1999) Cutting edge: identification of the orphan chemokine receptor GPR-9-6 as CCR9, the receptor for the chemokine TECK. J Immunol 162: 5671.
    • (1999) J Immunol , vol.162 , pp. 5671
    • Zaballos, A.1    Gutierrez, J.2    Varona, R.3    Ardavin, C.4    Márquez, G.5
  • 5
    • 0036910773 scopus 로고    scopus 로고
    • Involvement of CCL25 (TECK) in the generation of the murine small-intestineal CD8αα+CD3+ intraepithelial lymphocyte compartment
    • Marsal J, Svensson M, Ericsson A, Iranpour AH, Carramolino L, et al. (2002) Involvement of CCL25 (TECK) in the generation of the murine small-intestineal CD8αα+CD3+ intraepithelial lymphocyte compartment. Eur J Immunol 32: 3488-3497.
    • (2002) Eur J Immunol , vol.32 , pp. 3488-3497
    • Marsal, J.1    Svensson, M.2    Ericsson, A.3    Iranpour, A.H.4    Carramolino, L.5
  • 6
    • 0036802422 scopus 로고    scopus 로고
    • CCL25 mediates the localization of recently activated CD8αβ+ lymphocytes to the small-intestinal mucosa
    • Svensson M, Marsal J, Ericsson A, Carramolino L, Brodén T, et al. (2002) CCL25 mediates the localization of recently activated CD8αβ+ lymphocytes to the small-intestinal mucosa. J Clin Invest 110: 1113-1121.
    • (2002) J Clin Invest , vol.110 , pp. 1113-1121
    • Svensson, M.1    Marsal, J.2    Ericsson, A.3    Carramolino, L.4    Brodén, T.5
  • 7
    • 1342300522 scopus 로고    scopus 로고
    • Chemokine receptor CCR9 contributes to the localization of plasma cells to the small intestine
    • Pabst O, Ohl L, Wendland M, Wurbel MA, Kremmer E, et al. (2004) Chemokine receptor CCR9 contributes to the localization of plasma cells to the small intestine. J Exp Med 199: 411-416.
    • (2004) J Exp Med , vol.199 , pp. 411-416
    • Pabst, O.1    Ohl, L.2    Wendland, M.3    Wurbel, M.A.4    Kremmer, E.5
  • 8
    • 34547525608 scopus 로고    scopus 로고
    • CCR9 is a homing receptor for plasmacytoid dendritic cells to the small intestine
    • Wendland M, Czeloth N, Mach N, Malissen B, Kremmer E, et al. (2007) CCR9 is a homing receptor for plasmacytoid dendritic cells to the small intestine. Proc Natl Acad Sci USA 104: 6347-6352.
    • (2007) Proc Natl Acad Sci USA , vol.104 , pp. 6347-6352
    • Wendland, M.1    Czeloth, N.2    Mach, N.3    Malissen, B.4    Kremmer, E.5
  • 9
    • 77957244016 scopus 로고    scopus 로고
    • Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease
    • Walters MJ, Wang Y, Lai N, Baumgart T, Zhao BN, et al. (2010) Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. J Pharmacol Exp Ther 335: 65-69.
    • (2010) J Pharmacol Exp Ther , vol.335 , pp. 65-69
    • Walters, M.J.1    Wang, Y.2    Lai, N.3    Baumgart, T.4    Zhao, B.N.5
  • 11
    • 0024356033 scopus 로고
    • Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicenter study
    • Mary JY, Modigliani R, (1989) Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicenter study. Gut 30: 983-989.
    • (1989) Gut , vol.30 , pp. 983-989
    • Mary, J.Y.1    Modigliani, R.2
  • 12
    • 0036161216 scopus 로고    scopus 로고
    • A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease
    • Sandborn WJ, Feagan BG, Hanauer SB, Lochs H, Lofberg R, et al. (2002) A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 122: 512-530.
    • (2002) Gastroenterology , vol.122 , pp. 512-530
    • Sandborn, W.J.1    Feagan, B.G.2    Hanauer, S.B.3    Lochs, H.4    Lofberg, R.5
  • 13
    • 0034327830 scopus 로고    scopus 로고
    • The role of thymus-expressed chemokine and its receptor CCR9 on lymphocytes in the regional specialization of the mucosal immune system
    • Papadakis KA, Prehn J, Nelson V, Cheng L, Binder SW, et al. (2000) The role of thymus-expressed chemokine and its receptor CCR9 on lymphocytes in the regional specialization of the mucosal immune system. J Immunol 165: 5069-5076.
    • (2000) J Immunol , vol.165 , pp. 5069-5076
    • Papadakis, K.A.1    Prehn, J.2    Nelson, V.3    Cheng, L.4    Binder, S.W.5
  • 14
    • 0034899072 scopus 로고    scopus 로고
    • CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease
    • Papadakis KA, Prehn J, Moreno ST, Cheng L, Kouroumalis EA, et al. (2001) CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease. Gastroenterology 21: 246-254.
    • (2001) Gastroenterology , vol.21 , pp. 246-254
    • Papadakis, K.A.1    Prehn, J.2    Moreno, S.T.3    Cheng, L.4    Kouroumalis, E.A.5
  • 15
    • 84875131659 scopus 로고    scopus 로고
    • Presence of CCR9 and its ligand CCL25/TECK in the colon: scientific rationale for the use of CCR9 small molecule antagonist CCX282-B in colonic disorders
    • Walters MJ, Berahovich R, Wang Y, Wei Z, Ungashe S, et al. (2008) Presence of CCR9 and its ligand CCL25/TECK in the colon: scientific rationale for the use of CCR9 small molecule antagonist CCX282-B in colonic disorders. Gut 57 (Suppl II): A39 (OP184).
    • (2008) Gut , vol.57 , Issue.SUPPL. II
    • Walters, M.J.1    Berahovich, R.2    Wang, Y.3    Wei, Z.4    Ungashe, S.5
  • 17
    • 34247884424 scopus 로고    scopus 로고
    • Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial
    • Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, et al. (2007) Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial. Gastroenterology 132: 1672-1683.
    • (2007) Gastroenterology , vol.132 , pp. 1672-1683
    • Targan, S.R.1    Feagan, B.G.2    Fedorak, R.N.3    Lashner, B.A.4    Panaccione, R.5
  • 19
    • 32044451548 scopus 로고    scopus 로고
    • Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial
    • Hanauer SB, Sandborn WJ, Rutgeers P, Fedorak RN, Lukas M, et al. (2006) Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130: 323-333.
    • (2006) Gastroenterology , vol.130 , pp. 323-333
    • Hanauer, S.B.1    Sandborn, W.J.2    Rutgeers, P.3    Fedorak, R.N.4    Lukas, M.5
  • 20
    • 70449100743 scopus 로고    scopus 로고
    • Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study
    • Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lemann M, et al. (2009) Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 374; 1617-1625.
    • (2009) Lancet , vol.374 , pp. 1617-1625
    • Beaugerie, L.1    Brousse, N.2    Bouvier, A.M.3    Colombel, J.F.4    Lemann, M.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.